Fish oil with metformin did not yet reduce atherosclerosis markers in women with PMOS: RCT protocol.
This is a protocol paper describing a planned RCT, not results from a completed trial. The study will randomize 146 overweight or obese women aged 25-45 with PMOS and elevated triglycerides or apoB to receive either fish oil (5.96 g/day) or placebo for 12 months alongside standard metformin therapy. Primary outcomes are carotid intimal-medial thickness, carotid plaque height, and left ventricular strain; secondary outcomes include blood lipids and glucose-insulin measures.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 18, 2026 · Discovered: Sep 19, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- 146
- Duration
- 12 months
- Population
- Women aged 25-45 years with polyendocrine metabolic ovarian syndrome (PMOS), overweight or obesity (BMI >25 kg/m²), and elevated fasting plasma triglyceride or apoB levels
- Primary outcome
- Carotid intimal medial thickness, carotid plaque height, and left ventricular global longitudinal strain
- Effect size
- —
- Significance
- Not reported
- Journal
- BMJ Open
- Published
- Sep 18, 2026
Sources
Primary source
- BMJ open ↗Peer reviewed
Assessment history
9/24/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.